Deal Watch: Mylan Counts On A Renaissance For Expansion
Executive Summary
European markets are the name of the game as Ariad sells its European business to Incyte, Spain's Grupo Ferrer buys out Alexza, Italy's Chiesi bags a suite of CV drugs from The Medicines Co. and Swiss kidney disease specialist Vifor Fresenius takes up Opko's Rayaldee.
You may also be interested in...
Mylan Confident On Advair Generic First-Round Approval
President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.
Mylan Finally Nabs Meda In Diversification Play
Deal coincides with full year/fourth quarter earnings release.
Five-Plus-Five Equals A Focus On Execution At Lilly In 2023
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.